Perfusion-Based Antibody Production in the Ambr® 250 Modular
The perfusion mode has become increasingly important in biopharmaceutical production in recent years. A bioreactor system used in many laboratories for the development of monoclonal antibodies (mAbs) production processes is the Sartorius’ Ambr. 250 system. Vessels designed for perfusion mode are onl...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | deu |
| Published: |
Swiss Chemical Society
2025-05-01
|
| Series: | CHIMIA |
| Subjects: | |
| Online Access: | https://www.chimia.ch/chimia/article/view/7518 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849305577077866496 |
|---|---|
| author | Vivian Ott Jan Ott Andry D. Mannone Regine Eibl |
| author_facet | Vivian Ott Jan Ott Andry D. Mannone Regine Eibl |
| author_sort | Vivian Ott |
| collection | DOAJ |
| description | The perfusion mode has become increasingly important in biopharmaceutical production in recent years. A bioreactor system used in many laboratories for the development of monoclonal antibodies (mAbs) production processes is the Sartorius’ Ambr. 250 system. Vessels designed for perfusion mode are only available for its high throughput version, while the modular version of the Ambr 250 is not designed for perfusion mode. In this study, perfusion processes for the production of a mAb with Chinese Hamster Ovary (CHO) cells were realized in the Ambr 250 Modular in combination with Repligen’s ATF 1 single-use device for the first time, to the authors’ knowledge. After testing a semi-perfusion setup in well plates and the Ambr 250, an N−1 perfusion process was developed to produce ultra-high cell densities of more than 150 Å~ 106 cells mL−1 for the inoculation of subsequent mAb production processes. In a second step, continuous mAb production was successfully realized over 23 days in a proof-of-concept experiment, achieving a volumetric productivity of 0.65 g L−1 d−1. The results of the N−1 and continuous perfusion processes were comparable to a 3 L HyPerformaTM Glass bioreactor (Thermo Scientific) with an ATF 2 (Repligen).
|
| format | Article |
| id | doaj-art-e8be6d345d1a4ab593dc04565a4cbe77 |
| institution | Kabale University |
| issn | 0009-4293 2673-2424 |
| language | deu |
| publishDate | 2025-05-01 |
| publisher | Swiss Chemical Society |
| record_format | Article |
| series | CHIMIA |
| spelling | doaj-art-e8be6d345d1a4ab593dc04565a4cbe772025-08-20T03:55:24ZdeuSwiss Chemical SocietyCHIMIA0009-42932673-24242025-05-0179510.2533/chimia.2025.330Perfusion-Based Antibody Production in the Ambr® 250 ModularVivian Ott0https://orcid.org/0000-0002-0208-3909Jan Ott1https://orcid.org/0000-0003-2854-9604Andry D. Mannone2https://orcid.org/0009-0000-0264-8706Regine Eibl3https://orcid.org/0000-0002-1840-8253ZHAW Zurich University of Applied Sciences, School of Life Sciences and Facility Management, CH-8820 Wädenswil, SwitzerlandZHAW Zurich University of Applied Sciences, School of Life Sciences and Facility Management, CH-8820 Wädenswil, SwitzerlandZHAW Zurich University of Applied Sciences, School of Life Sciences and Facility Management, CH-8820 Wädenswil, SwitzerlandZHAW Zurich University of Applied Sciences, School of Life Sciences and Facility Management, CH-8820 Wädenswil, SwitzerlandThe perfusion mode has become increasingly important in biopharmaceutical production in recent years. A bioreactor system used in many laboratories for the development of monoclonal antibodies (mAbs) production processes is the Sartorius’ Ambr. 250 system. Vessels designed for perfusion mode are only available for its high throughput version, while the modular version of the Ambr 250 is not designed for perfusion mode. In this study, perfusion processes for the production of a mAb with Chinese Hamster Ovary (CHO) cells were realized in the Ambr 250 Modular in combination with Repligen’s ATF 1 single-use device for the first time, to the authors’ knowledge. After testing a semi-perfusion setup in well plates and the Ambr 250, an N−1 perfusion process was developed to produce ultra-high cell densities of more than 150 Å~ 106 cells mL−1 for the inoculation of subsequent mAb production processes. In a second step, continuous mAb production was successfully realized over 23 days in a proof-of-concept experiment, achieving a volumetric productivity of 0.65 g L−1 d−1. The results of the N−1 and continuous perfusion processes were comparable to a 3 L HyPerformaTM Glass bioreactor (Thermo Scientific) with an ATF 2 (Repligen). https://www.chimia.ch/chimia/article/view/7518ATFCHO cellsContinuous perfusionN−1 perfusionScale-down model |
| spellingShingle | Vivian Ott Jan Ott Andry D. Mannone Regine Eibl Perfusion-Based Antibody Production in the Ambr® 250 Modular CHIMIA ATF CHO cells Continuous perfusion N−1 perfusion Scale-down model |
| title | Perfusion-Based Antibody Production in the Ambr® 250 Modular |
| title_full | Perfusion-Based Antibody Production in the Ambr® 250 Modular |
| title_fullStr | Perfusion-Based Antibody Production in the Ambr® 250 Modular |
| title_full_unstemmed | Perfusion-Based Antibody Production in the Ambr® 250 Modular |
| title_short | Perfusion-Based Antibody Production in the Ambr® 250 Modular |
| title_sort | perfusion based antibody production in the ambr r 250 modular |
| topic | ATF CHO cells Continuous perfusion N−1 perfusion Scale-down model |
| url | https://www.chimia.ch/chimia/article/view/7518 |
| work_keys_str_mv | AT vivianott perfusionbasedantibodyproductionintheambr250modular AT janott perfusionbasedantibodyproductionintheambr250modular AT andrydmannone perfusionbasedantibodyproductionintheambr250modular AT regineeibl perfusionbasedantibodyproductionintheambr250modular |